4 years of RESONATE data for CLL patients treated with ibrutinib

Share :
Published: 28 Jun 2017
Views: 3334
Rating:
Save
Dr Carolina Moreno Atanasio - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Dr Carolina Moreno Atanasio speaks with ecancer at EHA 2017 to report on the 4 year review of ibrutinib for CLL in patients who had previously received tyrosine kinase therapy.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content. 

The results are really, really promising because what we have seen is that the efficacy of the drug after four years of follow-up is clear and that the progression free survival there is a reduction of the risk of progression in almost 80% of the patients, in patients treated with ibrutinib, as compared to those who received the control arm which was ofatumumab. This difference is also translated into a benefit in overall survival in these patients and I must say that the toxicity profile is very good. Over the years what we are seeing is that there is a decrease in adverse events at three years and a few patients had serious adverse events such as arterial fibrillation in around 10% of the patients and pneumonia in a low percentage of patients.

So in conclusion we can say that the long follow-up of this trial is confirming the good results that were published at the first interim analysis at nine months in terms of efficacy and toxicity.

Just a quick note, I did see there were some reasons for trial discontinuation. Could you tell us any more about that?

Yes, there was a percentage of discontinuation but half of the patients continued on therapy and the tolerability was quite good.